Corticosteroids Market Size Expected to Reach USD 6.91 Bn by 2033

The global corticosteroids market size is calculated at USD 4.76 billion in 2024 and is expected to reach around USD 6.91 billion by 2033, growing at a CAGR of 4.2% from 2024 to 2032.

Ottawa, April 18, 2024 (GLOBE NEWSWIRE) — The global corticosteroids market size was valued at USD 4.71 billion in 2023 and is predicted to hit around USD 6.45 billion by 2032, a study published by Towards Healthcare a sister firm of Precedence Research.

Report Highlights:

  • Rheumatology application led the charge in 2023 with a 35% market share.
  • Dermatology application is set to be the fastest-growing segment, boasting a 5.1% CAGR for healthier skin.
  • Topical corticosteroids reign supreme, dominating the market with a 49% share in 2023.

The Forum of International Respiratory Societies estimates that over 4.5 million people have lost their lives due to the current pandemic, primarily from respiratory issues. Corticosteroids have been widely employed in treating respiratory diseases during this crisis.

Corticosteroids are a class of steroid hormones produced by the adrenal cortex, the outer portion of the adrenal glands located on top of each kidney. These hormones regulate various physiological processes, including metabolism, immune response, and electrolyte balance. There are two main types of corticosteroids: glucocorticoids and mineralocorticoids. Glucocorticoids, such as cortisol, regulate metabolism and the immune system, while mineralocorticoids, such as aldosterone, play a role in maintaining electrolyte and water balance.

Download a short version of this report @ https://www.towardshealthcare.com/personalized-scope/5111

In medicine, synthetic corticosteroids are commonly used for their anti-inflammatory and immunosuppressive properties. These medications are referred to as corticosteroid drugs or simply steroids. They can be administered in various forms, including oral tablets, topical creams or ointments, inhaled preparations, and injections. Corticosteroids are prescribed to treat a wide range of medical conditions, including autoimmune disorders, allergies, asthma, inflammatory joint diseases, and certain skin conditions.

It’s important to note that healthcare professionals should carefully monitor the use of corticosteroids due to potential side effects and the need for appropriate dosage adjustments. Prolonged or inappropriate use of corticosteroids can lead to adverse effects such as bone loss, immune system suppression, and metabolic disturbances. Therefore, these medications are typically prescribed based on a thorough assessment of the patient’s condition and careful consideration of the potential risks and benefits.

The increasing incidence of respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), has led to a higher demand for inhaled corticosteroids as part of the treatment regimen for these conditions. Corticosteroids continue to be a component of cancer treatment protocols, helping to manage side effects associated with chemotherapy. As cancer research advances and new treatment modalities emerge, the demand for supportive medications like corticosteroids may increase.

Impact of Covid-19

The pharmaceutical industry, along with various others, has been significantly impacted by the COVID-19 pandemic. Despite corticosteroids not being antiviral drugs, they have emerged as crucial components in the treatment of severe COVID-19 cases, particularly in individuals experiencing serious lung complications. The heightened demand for corticosteroids during the pandemic can be attributed to several key factors. One pivotal role of corticosteroids is managing cytokine storms, which are intense immune responses triggered in severe COVID-19 cases. By modulating the immune system, corticosteroids help control these storms, reducing inflammation and safeguarding vital organs.

Additionally, the pandemic has seen an increase in cases of Acute Respiratory Distress Syndrome (ARDS) induced by COVID-19, characterized by severe lung inflammation. Corticosteroids alleviate this inflammation and enhance respiratory function in critically ill patients. Evidence from various clinical trials, including the influential RECOVERY trial, has supported using corticosteroids in severe COVID-19 cases. Notably, medications like dexamethasone have demonstrated effectiveness in reducing mortality rates, particularly in patients requiring respiratory support.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

For instance,

  • On 30 March 2023, the World Health Organization published an R&D Blueprint about the COVID-19 landscape of Novel Coronavirus Candidates Vaccine Development worldwide.

Major health organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), have responded to emerging evidence by updating their guidelines. These updates now recommend corticosteroids for specific severe cases of COVID-19, further contributing to the increased demand.

Many countries granted emergency approvals for using corticosteroids to address the urgency of treating severe COVID-19 cases. This facilitated quicker access to these medications for healthcare providers on the front lines of patient care. The surge in COVID-19 cases and subsequent hospitalizations during various waves of the pandemic heightened the demand for medications, including corticosteroids. Hospitals and healthcare systems proactively stocked up on these drugs to meet the needs of critically ill patients requiring intensive care.

The pandemic’s challenges have led to a boost in research efforts to understand the immune response to the virus better and identify effective treatment strategies. Corticosteroids have been explored in these research endeavors, being considered a valuable component in the evolving treatment plans against COVID-19.

Corticosteroids are Frequently Utilized in Managing Respiratory Ailments

Pulmonology’s application of corticosteroids, involving inhaling these medications directly into the lungs, is widely employed in managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD). This approach holds significant potential to drive the growth of the corticosteroid market for several compelling reasons.

For instance,

  • In 2020, around 1 million individuals went to the emergency room seeking care for asthma, and approximately 94,560 people had to be admitted to the hospital due to asthma. This high occurrence of pulmonary diseases emphasizes the need for effective treatment. Corticosteroids are commonly prescribed for pulmonary conditions to address the prevalent nature of these diseases.
  • In 2020, the National Institutes of Health conducted an extensive study involving 255,857 patients to look into how well inhaled treatments for Chronic Obstructive Pulmonary Disease (COPD), including triple therapy, work.

One key advantage of pulmonary application is its ability to provide localized treatment, delivering corticosteroids directly to the lungs where inflammation commonly occurs in respiratory conditions. This targeted delivery minimizes systemic exposure, mitigating the risk of systemic side effects while maximizing the therapeutic impact precisely at the site of inflammation. Compared to systemic administration methods, such as oral or injectable forms, inhaled corticosteroids generally exhibit lower systemic absorption. This characteristic reduces systemic side effects, such as bone loss or immune system suppression, making inhaled corticosteroids a preferred option for long-term use in chronic respiratory conditions.

Inhaled corticosteroids play a pivotal role in effectively managing inflammation within the airways, a fundamental aspect of respiratory diseases like asthma and COPD.

For instance,

  • As per The Forum of International Respiratory Societies, around 36% of kids aged 17 or younger with asthma in the United States had to go to the emergency room for asthma in the last year, according to pediatric studies. More corticosteroids are needed to treat respiratory diseases in this scenario.

This efficacy translates into improved symptom control, reduced exacerbations, and enhanced lung function. The convenience and patient-friendly nature of inhaled corticosteroids, typically administered through inhalers, contribute to increased patient compliance with prescribed treatment regimens. This adherence is crucial for effectively managing chronic respiratory conditions. The success of inhaled corticosteroids in managing respiratory conditions has prompted ongoing research into their potential application in other pulmonary disorders. This exploration could lead to an expanded range of indications for inhaled corticosteroids, further amplifying their demand in the market.

Combination therapies, wherein inhaled corticosteroids are paired with other respiratory medications like long-acting beta-agonists, offer a comprehensive approach to managing respiratory conditions. This integration contributes to the diversity of the market for respiratory medicines.

Customize this study as per your requirement @ https://www.towardshealthcare.com/customization/5111

Sr. No. Combination Therapy Indication
1. Inhaled corticosteroids (ICS) with long-acting bronchodilators (LABA) This combination is frequently used for asthma. The LABA opens airways while the ICS reduces inflammation. Examples include fluticasone/salmeterol (Advair) and budesonide/formoterol (Symbicort).
2. ICS with long-acting muscarinic antagonists (LAMA) This combination is commonly used for chronic obstructive pulmonary disease (COPD), another type of inflammatory lung disease. It targets different aspects of airway relaxation compared to ICS/LABA. Examples include fluticasone/umeclidinium/vilanterol (Trivento) and beclomethasone/glycopyrrolate/formoterol (Breztri Aerosphere).
3. Systemic Corticosteroids These are typically used for short-term management of severe exacerbations of various pulmonary diseases, including asthma and COPD. They reduce inflammation but have more side effects than inhaled corticosteroids.
4. Triple Therapy Combining ICS, LABA, and LAMA is sometimes used for patients with severe or poorly controlled COPD. This approach targets multiple mechanisms involved in the disease.

As respiratory conditions remain prevalent worldwide, the demand for targeted and effective treatments like inhaled corticosteroids is expected to drive the growth of the corticosteroid market. Ongoing developments in formulations, devices, and combination therapies further enhance the market potential for the pulmonary application of corticosteroids.

Challenge Occurs Due to High Cost of Corticosteroids Medications

The cost of corticosteroid medications, used to treat various medical conditions, can differ from one type of medication to another. Some newer versions or combinations of these medications might be more expensive. This can worry patients because if the medicines are too costly, it might be challenging to afford and get the treatment they need.

Imagine if you have a health issue requiring corticosteroids, and different options are available. Some of these options might be more advanced or combined with other medications to make the treatment more effective. However, these newer or combined versions might be pricier than the older ones.

For instance,

  • According to reports from the Forum of International Respiratory Societies, the widespread occurrence and seriousness of the illness lead to a high economic burden. For instance, treating Chronic Obstructive Pulmonary Disease (COPD) directly costs about 6% of the entire healthcare spending (USD 41.5 billion every year) in the European Union. This represents more than half (56%) of the total expenses for treating respiratory diseases.

Affordability is a concern because if the medication is too expensive, some people might have trouble paying for it. This, in turn, can affect their ability to access the necessary treatment. Healthcare providers and policymakers need to consider these cost factors to ensure that people can afford the medications they need for their health. This way, everyone has a fair chance to get the treatment that can help them feel better without facing financial difficulties.

Browse More Insights of Towards Healthcare:

  • The 503A U.S. compounding pharmacies market size is estimated to grow from USD 3.99 billion in 2022 to surpass around USD 7.18 billion by 2032, growing at a 6.11% CAGR between 2023 and 2032.
  • The global generative AI in healthcare market was valued at USD 1.07 billion in 2022 to reach an estimated USD 21.74 billion by 2032, growing at a CAGR of 35.1% from 2023 to 2032.
  • The global chatbots for mental health and therapy market size to grow from USD 0.99 billion in 2022 to reach around USD 6.51 billion by 2032, registered at a CAGR of 21.3% between 2023 to 2032.
  • The global brain implants market was valued at USD 5.85 billion in 2022 and is projected to reach around USD 14.24 billion by 2032, expanding at a CAGR of 9.3% between 2023 and 2032.
  • The global lung disease therapeutics market size was valued at USD 81.2 billion in 2022 and is projected to hit around USD 146.1 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032.
  • The global genomics market size to grow from USD 28.9 billion in 2022 to reach around USD 127.16 billion by 2032, registered at a CAGR of 16.1% between 2023 and 2032.
  • The global non-oncology precision medicine market size was at USD 70.16 billion in 2022 and is projected to surpass around USD 163.5 billion by 2032, growing at a CAGR of 8.7% from 2023 to 2032.
  • The global non-invasive blood glucose monitoring system market size to grow from USD 21.76 million in 2022 to reach around USD 202.73 million by 2032, at 25.0% CAGR between 2023 and 2032.
  • The global animal vaccine market was estimated to grow from USD 14.27 billion in 2022 to soar an estimated USD 36.91 billion by 2032, at 10% CAGR between 2023 and 2032.
  • The global pancreatic cancer market size was at USD 2.05 billion in 2022 and is projected to reach around USD 7.4 billion by 2032, expanding at a CAGR of 13.7%.

Geographical Landscape

North America boasts a well-developed healthcare infrastructure with advanced medical facilities, research institutions, and a high standard of healthcare delivery. This infrastructure supports diagnosing, treating, and managing a wide range of conditions, contributing to the demand for corticosteroid medications. Respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), are prevalent in North America. The region’s corticosteroid market is significantly influenced by the demand for inhaled corticosteroids, commonly prescribed for managing these respiratory disorders. Respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD), are prevalent in North America. The region’s corticosteroid market is significantly influenced by the demand for inhaled corticosteroids, commonly prescribed for managing these respiratory disorders. The ongoing collaboration between healthcare stakeholders, including government agencies, healthcare providers, and the pharmaceutical industry, continues to influence the landscape and ensure the effective use of corticosteroids in patient care.

The Asia-Pacific region is home to a large and diverse population, including developed and emerging economies. The sheer size and diversity of the population contribute to a significant market for corticosteroid medications to address various health needs. The region is witnessing increased research and development initiatives in the pharmaceutical sector. Ongoing efforts focus on developing new formulations, combination therapies, and targeted corticosteroid delivery methods, contributing to market growth. Some countries in the Asia-Pacific region are considered emerging markets for pharmaceuticals. The growing middle class, urbanization, and increasing healthcare investments create opportunities to expand the corticosteroid market.

Competitive Landscape

The competitive landscape for the corticosteroid market is shaped by a mix of global pharmaceutical companies, regional players, and a diverse range of corticosteroid products catering to various therapeutic areas. Companies in the corticosteroid market offer a diverse range of products, including oral tablets, topical creams, ointments, nasal sprays, inhalers, and injectables. This diverse portfolio allows them to address various medical conditions, from skin disorders to respiratory and autoimmune diseases. Understanding the competitive landscape involves considering the intricate balance between innovation, market expansion, regulatory compliance, and strategic partnerships. Companies that effectively navigate these factors are well-positioned to thrive in the corticosteroid market.

Recent Developments

  • In August 2022, a test was done to see if Vamorolone could help treat Becker muscular dystrophy (BMD). The first patient got a dose of nandrolone in this study by ReveraGen BioPharma. They are looking into whether this steroid medicine could be a cure for different types of muscular dystrophy.
  • In April 2022, Eli Lilly and Company mixed Lebrikizumab with topical corticosteroids to treat atopic dermatitis (AD), a skin condition. After 16 weeks of testing, 75% improvement was seen in patients. When combined in these crucial trials, Lebrikizumab significantly impacted critical areas for people with atopic dermatitis, like the skin and itch.

Market Players

  • Pfizer
  • Novartis
  • Merck & Co., Inc.
  • GlaxoSmithKline
  • AstraZeneca
  • Bausch Health Companies Inc.
  • Galderma
  • Cipla
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Market Segments

By Product Type

  • Glucocorticoids
  • Mineralocorticoids
  • Synthetic Corticosteroids

By Route of Administration

  • Topical
  • Oral
  • Inhaled
  • Injectable
  • Ophthalmic

By Application

  • Rheumatology
  • Dermatology
  • Pulmonology
  • Gastroenterology
  • Neurology
  • Other Applications

By Product Form

  • Oral
  • Intravenous
  • Nasal
  • Topical

By End User

  • Hospitals and Clinics
  • Pharmacies and Retail
  • Specialty Clinics
  • Other End Users

By Geography

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5111

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Web: https://www.towardshealthcare.com

Browse our Brand-New Journal@ https://www.towardspackaging.com

Browse our Brand-New Journal@ https://towardsautomotive.com

Browse our Consulting Website@ https://www.precedenceresearch.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Privacy & Cookies Policy